Ionis Pharmaceuticals Files 8-K Report
Ticker: IONS · Form: 8-K · Filed: Sep 12, 2024 · CIK: 874015
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
Related Tickers: IONS
TL;DR
IONIS filed an 8-K. Check for updates on events & financials.
AI Summary
On September 9, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific monetary figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Ionis Pharmaceuticals is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard SEC disclosure (8-K) and the provided excerpt does not contain information indicating significant new risks.
Key Players & Entities
- IONIS PHARMACEUTICALS, INC. (company) — Registrant
- 2855 Gazelle Court Carlsbad, CA 92010 (location) — Principal Executive Offices
- September 9, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Ionis Pharmaceuticals?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating disclosures of significant occurrences and financial information.
When was the earliest event reported in this filing?
The earliest event reported is dated September 9, 2024.
What is Ionis Pharmaceuticals' principal executive office address?
The address is 2855 Gazelle Court, Carlsbad, CA 92010.
What is the Commission File Number for Ionis Pharmaceuticals?
The Commission File Number is 000-19125.
What is the IRS Employer Identification Number for Ionis Pharmaceuticals?
The IRS Employer Identification Number is 33-0336973.
Filing Stats: 791 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-09-11 18:02:54
Key Financial Figures
- $0.001 — 0 shares of its common stock, par value $0.001 per share (" Common Stock "), at a pric
- $43.50 — n Stock "), at a price to the public of $43.50 per share. Pursuant to the Underwriting
- $42.6020 — f Common Stock from Ionis at a price of $42.6020 per share. Ionis also granted the Under
- $500.3 m — is from the Offering were approximately $500.3 million, before deducting underwriting di
Filing Documents
- d865048d8k.htm (8-K) — 28KB
- d865048dex11.htm (EX-1.1) — 163KB
- d865048dex51.htm (EX-5.1) — 8KB
- g865048g57d67.jpg (GRAPHIC) — 4KB
- 0001193125-24-217333.txt ( ) — 369KB
- ions-20240909.xsd (EX-101.SCH) — 2KB
- ions-20240909_lab.xml (EX-101.LAB) — 17KB
- ions-20240909_pre.xml (EX-101.PRE) — 11KB
- d865048d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 * Underwriting Agreement, dated September 9, 2024. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. I ONIS P HARMACEUTICALS , I NC . Dated: September 11, 2024 By: /s/ Patrick R. O'Neil P ATRICK R. O'N EIL Executive Vice President, Chief Legal Officer and General Counsel